Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 358-363

  Wang, Jing Houng ^a   Kee, Kwong Ming ^a   Lin, Chih Yun ^a   Hung, Chao Hung ^a   Chen, Chien Hung ^a   Lee, Chuan Mo ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Barcelona Clinic Liver Cancer (BCLC) intermediate stage; Hepatocellular carcinoma (HCC); Substage; Survival

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INTERMEDIATE HEPATOCELLULAR CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; UP TO SEVEN CRITERIA; VALIDATION PROCESS; AGED; ARTIFICIAL EMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; FOLLOW UP; FORECASTING; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; TIME FACTOR; VALIDATION STUDY;

AGED; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84921499517     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12686     Document Type: Article

References (29)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
2. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
3. Omata M, Lesmana LA, Tateishi R etal. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 2010; 4: 439-474.
4. Bolondi L, Burroughs A, Dufour JF etal. Heterogeneity of patients with intermediate (BCLC) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin. Liver Dis. 2012; 32: 348-359.
5. Park JW, Amarapurkar D, Chao Y etal. Consensus recommendations and review by an international expert panel on interventions in hepatocellular carcinoma (EPOIHCC). Liver Int. 2013; 33: 327-337.
6. Chung YH, Han G, Yoon JH etal. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int. J. Cancer 2013; 132: 2448-2458.
7. Mazzaferro V, LIovet JM, Miceli R etal. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35-43.
8. Wang JH, Changchien CS, Hu TH etal. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients. Eur. J. Cancer 2008; 44: 1000-1006.
9. Piscaglia F, Pecorelli A, Venerandi L etal. Clinical validation of a sub-staging proposal of patients with intermediate HCC (BCLC-B). J. Hepatol. 2013; 58 (Suppl. 1): S48-S49.
10. Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J. Gastroenterol. Hepatol. 2014; 29: 787-793.
11. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-430.
12. Cheng Y, Kan Z, Chen C etal. Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study. World J. Surg. 2000; 24: 844-850.
13. Armitage P, Colton T, eds. Encyclopedia of Biostatics. Chichester: Wiley, 1998; 123-124.
14. Zhong JH, Ke Y, Gong WF etal. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 2014; 260: 329-340.
15. Heng-Jun G, Yao-Jun Z, Min-Shan C etal. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int. 2014; 34: 612-620.
16. Chen CH, Hu FC, Huang GT etal. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur. J. Cancer 2009; 45: 1630-1639.
17. Georgiades C, Liapi E, Frangakis C etal. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J. Vasc. Interv. Radiol. 2006; 17: 1619-1624.
18. Takayasu K, Arii S, Ikai I etal. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
19. Terzi E, Golfieri R, Piscaglia F etal. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J. Hepatol. 2012; 57: 1258-1267.
20. Liu C, Xiao GQ, Yan LN etal. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J. Gastroenterol. 2013; 19: 1811-1819.
21. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.
22. Leung TW, Tang AM, Zee B etal. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769.
23. Hsu CY, Huang YH, Hsia CY etal. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J. Hepatol. 2010; 53: 108-117.
24. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013; 19: 634-645.
25. Vitale A, Volk ML, Maria De Feo T etal. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J. Hepatol. 2014; 60: 290-297.
26. Lencioni R, Kudo M, Ye SL etal. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int. J. Clin. Pract. 2012; 66: 675-683.
27. Shi M, Chen JA, Lin XJ etal. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern china. World J. Gastroenterol. 2010; 16: 264-269.
28. Chen PH, Kao WY, Chiou YY etal. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Ann. Hepatol. 2013; 12: 263-273.
29. Chen CH, Huang GT, Yang PM etal. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur. J. Cancer 2006; 42: 2524-2529.